<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36717323</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1879</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis</Title><ISOAbbreviation>Clin Investig Arterioscler</ISOAbbreviation></Journal><ArticleTitle>Prevalence of atherogenic dyslipidemia, related factors and level of lipid control in the general population of Galicia. GALIPEMIAS study.</ArticleTitle><Pagination><StartPage>178</StartPage><EndPage>184</EndPage><MedlinePgn>178-184</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arteri.2022.11.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0214-9168(22)00137-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">GALIPEMIAS is a study designed to establish the prevalence of familial dyslipidemia in the general population of Galicia. The objective of the present study was to assess the prevalence of atherogenic dyslipidemia (AD), its relationship with other cardiovascular risk (CVR) factors, and the degree of lipid control.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional study carried out in the general population over 18 years of age residing in Galicia and with a health card from the Galician Health Service (N=1,000). Selection of the sample by means of random sampling by conglomerates. The AD prevalence adjusted for age and sex and the related variables were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of AD adjusted for age and sex was 6.6% (95% CI: 5.0-8.3%). Arterial hypertension, altered basal glycemia, type 2 diabetes mellitus and cardiovascular disease were more frequent in subjects with AD than in the rest of the population. 47.5% of the subjects with AD had a high or very high CVR. Lipid-lowering drugs were received by 38.9% (30.5% statins) of the participants with AD (46.1% of those with high and 71.4% of those with very high CVR). 25.4% of the subjects with AD had target LDL-c levels, all of them with low or moderate CVR.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prevalence of AD in the general adult population of Galicia is not negligible, and it was related to several CVR factors and cardiovascular disease. Despite this, this lipid alteration was underdiagnosed and undertreated.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Publicado por Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>N&#xe1;zara</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Atenci&#xf3;n Primaria de Mar&#xed;n, Mar&#xed;n, Pontevedra, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arg&#xfc;eso</LastName><ForeName>Rosa M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital Universitario Lucus Augusti, Lugo, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedro-Botet</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidad de L&#xed;pidos y Riesgo Vascular, Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital del Mar; Universitat Aut&#xf2;noma de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pint&#xf3;</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Unidad de Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario Bellvitge, CiberObn, Idibell, Fipec, Universidad de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mill&#xe1;n</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidad de L&#xed;pidos, Servicio de Medicina Interna, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n; Facultad de Medicina Universidad Complutense, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pena Seijo</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n P&#xfa;blica Urgencias Sanitarias de Galicia-061, Santiago de Compostela, A Coru&#xf1;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Pablo A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital de Montecelo, Pontevedra, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eugenia Ameneiros</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Hospital Arquitecto Marcide, Ferrol, A Coru&#xf1;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Alamo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Atenci&#xf3;n Primaria Novoa Santos, Ourense, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Avelino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Hospital &#xc1;lvaro Cunqueiro, Vigo, Pontevedra, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-Peromingo</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coru&#xf1;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;zquez Freire</LastName><ForeName>Mar&#xed;a Rosa</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Centro de Salud Os Rosales, A Coru&#xf1;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;iz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universidad de A Coru&#xf1;a, Grupo de Investigaci&#xf3;n Cardiovascular (GRINCAR), Instituto Universitario de Ciencias de la Salud e Instituto de Investigaci&#xf3;n Biom&#xe9;dica de A Coru&#xf1;a (INIBIC), A Coru&#xf1;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Castro</LastName><ForeName>Teresa R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Universidad de A Coru&#xf1;a, Grupo de Investigaci&#xf3;n Cardiovascular (GRINCAR), Instituto Universitario de Ciencias de la Salud e Instituto de Investigaci&#xf3;n Biom&#xe9;dica de A Coru&#xf1;a (INIBIC), A Coru&#xf1;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-D&#xed;az</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Unidad de L&#xed;pidos y Riesgo Cardiovascular Servicio de Medicina Interna, Complejo Hospitalario Universitario de A Coru&#xf1;a, A Coru&#xf1;a, Espa&#xf1;a. Electronic address: Jose.luis.diaz.diaz@sergas.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pose Reino</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coru&#xf1;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prevalencia de dislipemia aterog&#xe9;nica, factores relacionados y grado de control lip&#xed;dico en la poblaci&#xf3;n general de Galicia. Estudio GALIPEMIAS.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Clin Investig Arterioscler</MedlineTA><NlmUniqueID>9208512</NlmUniqueID><ISSNLinking>0214-9168</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="Y">Dyslipidemias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atherogenic dyslipidemia</Keyword><Keyword MajorTopicYN="N">Atherosclerotic cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Cardiovascular risk</Keyword><Keyword MajorTopicYN="N">Colesterol LDL</Keyword><Keyword MajorTopicYN="N">Dislipemia aterog&#xe9;nica</Keyword><Keyword MajorTopicYN="N">Enfermedad cardiovascular ateroscler&#xf3;tica</Keyword><Keyword MajorTopicYN="N">LDL cholesterol</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">Prevalencia</Keyword><Keyword MajorTopicYN="N">Riesgo cardiovascular</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>30</Day><Hour>21</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36717323</ArticleId><ArticleId IdType="doi">10.1016/j.arteri.2022.11.002</ArticleId><ArticleId IdType="pii">S0214-9168(22)00137-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35099898</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1606-7916</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>6, Nov-Dic</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>Salud publica de Mexico</Title><ISOAbbreviation>Salud Publica Mex</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>705</StartPage><EndPage>712</EndPage><MedlinePgn>705-712</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21149/13163</ELocationID><Abstract><AbstractText>Objetivo. Analizar la asociaci&#xf3;n entre seropositividad a SARS-CoV-2 y enfermedades cr&#xf3;nicas en adultos y adultos mayores mexicanos. Material y m&#xe9;todos. Se utiliz&#xf3; la Encuesta Nacional de Salud y Nutrici&#xf3;n 2020 sobre Covid-19 (Ensanut 2020 Covid-19) para evaluar la asociaci&#xf3;n de seropositividad a SARS-CoV-2 con hipertensi&#xf3;n arterial sist&#xe9;mica, diabetes tipo 2, &#xed;ndice de masa corporal, LDL-c elevado, HDL-c bajo, colesterol total elevado e hipertrigliceridemia. Resultados. Se observ&#xf3; una mayor seropositividad en personas con mayor &#xed;ndice de masa corporal. La seroprevalencia fue 25% mayor entre los adultos que presentaban obesidad en comparaci&#xf3;n con aquellos de peso normal en modelos ajustados (RP: 1.25 IC95%: 1.08,1.46). No se observ&#xf3; asociaci&#xf3;n entre seropositividad y otras enfermedades cr&#xf3;nicas en adultos o adultos mayores. Conclusiones. Las personas con obesidad podr&#xed;an tener una mayor susceptibilidad a la infecci&#xf3;n por SARS-CoV-2. Este hallazgo debe ser confirmado con estudios longitudinales. No se encontr&#xf3; evidencia de asociaci&#xf3;n para otras enfermedades.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>S&#xe1;nchez-P&#xe1;jaro</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Salud Poblacional, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. andres.sanchez@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez Ferrer</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Conacyt-Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. carolina.perez@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basto-Abreu</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Salud Poblacional, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. ana.basto@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Dommarco</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n General, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. jrivera@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barquera</LastName><ForeName>Sim&#xf3;n</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Nutrici&#xf3;n y Salud, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. sbarquera@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denova-Guti&#xe9;rrez</LastName><ForeName>Edgar</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Nutrici&#xf3;n y Salud, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. edgar.denova@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrientos-Guti&#xe9;rrez</LastName><ForeName>Tonatiuh</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Salud Poblacional, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. tbarrientos@insp.mx.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Seroprevalencia de SARS-CoV-2 en adultos y adultos mayores en M&#xe9;xico y su asociaci&#xf3;n con enfermedades cr&#xf3;nicas. Ensanut 2020 Covid-19.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Salud Publica Mex</MedlineTA><NlmUniqueID>0404371</NlmUniqueID><ISSNLinking>0036-3634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>31</Day><Hour>15</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35099898</ArticleId><ArticleId IdType="doi">10.21149/13163</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28916128</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1879</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis</Title><ISOAbbreviation>Clin Investig Arterioscler</ISOAbbreviation></Journal><ArticleTitle>Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. EROMOT study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>9</EndPage><MedlinePgn>1-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arteri.2017.07.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0214-9168(17)30089-X</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Determination of the level of achievement of the low density lipoprotein cholesterol (LDL-C) therapeutic target in patients with high and very high vascular risk treated in Lipid Units, as well as the causes of non-achievement.</AbstractText><AbstractText Label="PATIENTS AND METHOD" NlmCategory="METHODS">Multicentre retrospective observational study that included patients over 18 years with high and very high vascular risk, according to the criteria of the 2012 European Guidelines on Cardiovascular Disease Prevention, referred consecutively to Lipid Units between January and June 2012 and with follow-up two years after the first visit.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included a total of 243 patients from 16 lipid units. The mean age was 52.2 years (SD 13.7), of whom 62.6% were males, and 40.3% of them were very high risk. At the first visit, 86.8% (25.1% in combination) and 95.0% (47.3% in combination) in the second visit (P&lt;.001) were treated with lipid-lowering treatment. The therapeutic target was achieved by 28% (95 CI: 22.4-34.1). As regards the causes of non-achievement, 24.6% were related to the medication (10.3% maximum tolerated dose and 10.9% due to the appearance of adverse effects), 43.4% due to the physician (19.4% by inertia, 13.7% considering that target already reached), and 46.9% due to the patient, highlighting the therapeutic non-compliance (31,4%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LDL-C targets were achieved in about one-third of patients. The low adherence of the patient, followed by medical inertia are the most frequent causes that can explain these results.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Sociedad Espa&#xf1;ola de Arteriosclerosis. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Clotilde</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servei de Medicina Interna, Unitat de L&#xed;pids i Risc Vascular, Althaia Xarxa Assistencial Universit&#xe0;ria de Manresa, Manresa, Barcelona, Espa&#xf1;a. Electronic address: cmorales@althaia.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plana</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Unitat de Medicina Vascular i Metabolisme (UVASMET), Hospital Universitari Sant Joan de Reus, Universitat Rovira i Virgili de Reus, Reus, Tarragona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnau</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unitat de Recerca i Innovaci&#xf3;, Althaia Xarxa Assistencial Universit&#xe0;ria de Manresa, Manresa, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matas</LastName><ForeName>Laia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servei de Medicina Interna, Unitat de Risc Vascular i L&#xed;pids, Hospital de Sant Pau de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauri</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servei de Medicina Interna, Unitat de L&#xed;pids, Consorci Sanitari de Terrassa-Hospital de Terrassa, Terrassa, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vila</LastName><ForeName>&#xc0;lex</ForeName><Initials>&#xc0;</Initials><AffiliationInfo><Affiliation>Servei de Medicina Interna, Unitat de L&#xed;pids, Hospital de Figueres, Figueres, Girona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vila</LastName><ForeName>Llu&#xed;s</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servei d'Endocrinologia i Nutrici&#xf3;, Unitat de L&#xed;pids, Hospital Sant Joan Desp&#xed; Mois&#xe8;s Broggi, Consorci Sanitari Integral, Sant Joan Desp&#xed;, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soler</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital de Santa Caterina de Salt, Parc Hospitalari Mart&#xed; i Juli&#xe0;, Salt, Girona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montesinos</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unitat de Recerca i Innovaci&#xf3;, Althaia Xarxa Assistencial Universit&#xe0;ria de Manresa, Manresa, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masana</LastName><ForeName>Llu&#xed;s</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unitat de Medicina Vascular i Metabolisme (UVASMET), Hospital Universitari Sant Joan de Reus, Universitat Rovira i Virgili de Reus, Reus, Tarragona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedro-Botet</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unitat de L&#xed;pids i Risc Vascular, Hospital del Mar, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>en nombre del grupo de Investigadores EROMOT-XULA</CollectiveName></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><VernacularTitle>Causas de no consecuci&#xf3;n del objetivo terap&#xe9;utico del colesterol de las lipoprote&#xed;nas de baja densidad en pacientes de alto y muy alto riesgo vascular controlados en Unidades de L&#xed;pidos y Riesgo Vascular. Estudio EROMOT.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Clin Investig Arterioscler</MedlineTA><NlmUniqueID>9208512</NlmUniqueID><ISSNLinking>0214-9168</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000960">Hypolipidemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="N">Dyslipidemias</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000960" MajorTopicYN="N">Hypolipidemic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colesterol de las lipoprote&#xed;nas de baja densidad</Keyword><Keyword MajorTopicYN="N">Lipid Units</Keyword><Keyword MajorTopicYN="N">Low density lipoprotein cholesterol</Keyword><Keyword MajorTopicYN="N">Objetivo terap&#xe9;utico</Keyword><Keyword MajorTopicYN="N">Therapeutic target</Keyword><Keyword MajorTopicYN="N">Unidades de L&#xed;pidos</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28916128</ArticleId><ArticleId IdType="doi">10.1016/j.arteri.2017.07.003</ArticleId><ArticleId IdType="pii">S0214-9168(17)30089-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15559229</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Print"><Volume>140</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>[Cholesterol goal attainment with lipid lowering drugs. The COMETA Mexico Trial].</ArticleTitle><Pagination><StartPage>493</StartPage><EndPage>501</EndPage><MedlinePgn>493-501</MedlinePgn></Pagination><Abstract><AbstractText>In a retrospective study to determine rate of patients attaining therapeutic LDL-C goal values with lipid-lowering drugs, 20 specialists and general practitioners were selected who enrolled 120 patients whose lipids were measured after at least 12 weeks of treatment. They were grouped in three categories: group A (absolute risk of CHD in 10 years &lt;10%); group B, with 10-20% risk, and group C, with &gt;20% risk. Goal LDL-C values were &lt;160 mg/dL for group A, &lt;130 for group B, and &lt;100 for group C. Mean age was 57 +/- 12 years, 59% were males, and 51% were in group C; 83% took statins, 12% fibrates alone, and 5%, combinations. Atorvastatin and simvastatin were the most used drugs, at medium doses (mean 12 and 27 mg/day). LDL-C was reduced 25%; overall, 22% of patient doses were adjusted. Therapeutic goals were attained in 29% with initial doses and 42% at the end of study. Goal values were better attained in groups with lower risk. No differences were noticed among distinct physician categories. Data show poor compliance with international guidelines and insufficient attainment of therapeutic goals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meaney</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unidad Cardiovascular del Hospital Regional 1 de Octubre del ISSSTE, M&#xe9;xico, DF. lalitomini@prodigy.net.mx</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vela</LastName><ForeName>Agust&#xed;n</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Alma</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Alemao</LastName><ForeName>Evo</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><VernacularTitle>Cumplimiento de las metas con reductores del colesterol en pacientes mexicanos. El estudio COMETA M&#xe9;xico.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006949" MajorTopicYN="N">Hyperlipidemias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008511" MajorTopicYN="N">Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="Y">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013038" MajorTopicYN="N">Specialization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15559229</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>